General Range
Norsunate-100
Price on request/100 · MOQ 100 boxes
Norsunate-100 Tablets by Enormmed Pharma Private Limited contain Artesunate 100 mg, an artemisinin-derived antimalarial medicine used as part of appropriate combination therapy for the treatment of malaria caused by susceptible Plasmodium parasites.
Artesunate is a rapidly acting antimalarial agent that helps reduce malaria parasites in the bloodstream. Its active metabolite, dihydroartemisinin, acts against the parasite's blood stages, contributing to rapid parasite clearance.
Norsunate-100 Tablets may be prescribed as a component of artemisinin-based combination therapy for uncomplicated malaria, particularly infections caused by Plasmodium falciparum, according to applicable treatment guidelines. Artesunate must be combined with an appropriate partner antimalarial medicine to improve treatment effectiveness and reduce the development of resistance.
The medicine should only be taken under the supervision of a registered medical practitioner. The treatment regimen depends on the malaria species, patient's body weight, clinical condition and local treatment guidelines.
CategoryGeneral Range
Min. Order100 boxes
Supplied byEnorm Med Pharma Pvt. Ltd.
CertificationWHO-GMP, ISO
Prices are indicative and set by the listing company. Confirm net rates, packing and stock availability directly with the supplier.
Specifications
- Composition
- Artesunate Tablets
- Packaging Type
- Tablets
- Packaging Size
- 20 × 1 × 4
- Dosage Form
- Tablet
- Treatment
- Used as part of artemisinin-based combination therapy (ACT) for uncomplicated malaria.
- Shelf Life
- 24 Months
- Storage
- Store below 30°C, protect from light & moisture
- Certification
- WHO-GMP, ISO
Company Info
Enorm Med Pharma Pvt. Ltd.Panchkula, Haryana
Enorm Med Pharma Private Limited is an Indian pharmaceutical company based in Panchkula, Haryana, specializing in the manufacture, trade, wholesale, and export of a wide range of pharmaceutical formulations.
Company Overview
• Incorporation / Establishment: Originally started as a proprietorship in 2021, later incorporated as a private limited company on April 9, 2023 (CIN: U46497HR2023PTC110540).
• Registered Address: SCO 272, Sector-20, Panchkula, Haryana – 134116, India.
• Directors / Leadership: Sukhinder Jindal and Gurpreet Jindal.
• Certifications: ISO 9001:2015 and WHO-GMP compliant operations/standards.
• Business Model: PCD (Propaganda Cum Distribution) Pharma Franchise, third-party manufacturing, wholesale distribution, and domestic/global supply.
Product Portfolio
Enorm Med Pharma deals in diverse therapeutic segments and dosage forms, including:
• Dosage Forms: Tablets, capsules, softgelatin capsules, syrups, dry syrups, injections (vials), and ointments.
• Therapeutic Ranges: Anti-infectives, cardiac, diabetic, dermatology, and general wellness/herbal formulas.
• Notable Branded Products: Azeenorm (Azithromycin), Diclonorm, Enomzole-D, Levonorm, Pantenorm, Norsunate (Artesunate injections), and Mebenorm.
More General Range
